Orlifit 120mg Capsule

Orlifit 120mg Capsule

Orlifit 120mg Capsule

Orlifit 120mg Capsule

650.00

In stock

650.00


Pack Size :         10’s


Composition :     Orlistat


Pharmaceutical form :  Capsule


Brand Name : GETZ PHARMA


 

Description

Orlifit 120mg Capsule

Orlifit 120mg Capsule (Orlistat) is the first drug in a new class of nonsystemically acting anti-obesity drugs known as lipase inhibitors. Chemically Orlifit 120mg Capsule is (S)-2-formylamino-4-methyl-pentanoic acid (S)-1-[[(2S, 3S)-3-hexyl-4-oxo-2-oxetanyl] methyl]- dodecyl ester. The molecular formula is C29H53NO5 . Orlifit 120mg Capsuleis used in combination with diet adjustment in obese patients to manage their weight. Organic causes of obesity, such as hypothyroidism, should be excluded before prescribing Orlifit 120mg Capsule – Orlifit 120mg Capsule should be stopped after 3 months if the patient has not lost 5% of body weight and stopped at 6 months if the patient has not lost 10% of body weight. – The daily intake of fat should be distributed over three main meals. If Orlifit 120mg Capsule is taken with any one meal very high in fat, the possibility of gastrointestinal effects may increase. – Weight loss induced by Orlifit 120mg Capsule accompanied by improved metabolic control in type 2 diabetics might require reduction in the dose of hypoglycemic medication (e.g., sulfonylureas). Cyclosporine A decrease in cyclosporine plasma levels has been observed, when Orlifit 120mg Capsule was administered concomitantly. Therefore the combination is not recommended. However, if such concomitant use is unavoidable, to reduce the chance of drug-drug interaction cyclosporine should be taken 2 hours after or before Orlifit 120mg Capsule. It is  used in combination with diet adjustment in obese patients to manage their weight

Uses

Orlifit 120mg Capsule is used in combination with diet adjustment in obese patients to manage their weight

 Side effects

Patients administered with this medication may experience headache, dizziness, throat irritation, cough, dry mouth, and nausea. Patients may also experience constipation, urinary retention (inability to urinate completely), occasional paradoxical bronchospasm (narrowing or spasm of airway), tachycardia (increased heart rate), and arrhythmias (disorder of heart rhythm)

When not use

Orlifit 120mg Capsule is contraindicated in case of hypersensitivity to the active substance i.e. ipratropium bromide or to atropine.

Reviews

There are no reviews yet.


Be the first to review “Orlifit 120mg Capsule”